A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Summary

The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor (ARPI) or taxane-based chemotherapy. We plan to recruit 90 participants who will be randomly assigned to 1 of 3 dose cohorts (30 cases per dose cohort) with up to 6 cycles of treatment in this study.

Timeline

Start

2026-05-22

Primary completion

2027-12-30

Completion

2029-12-30

Drugs

Indications